Safety and Preliminary Efficacy of Ceritinib 450 mg with Food in Chinese ALK-positive Non-small Cell Lung Cancer

Safety and Preliminary Efficacy of Ceritinib 450 mg with Food in Chinese ALK-positive Non-small Cell Lung Cancer

Background and objective Anaplastic lymphoma kinase (ALK) rearrangement is a common driver gene of non-small cell lung cancer (NSCLC). Ceritinib is a second-generation ALK inhibitor, which can bring survival benefits to ALK-positive metastatic NSCLC. However, few studies focus on the safety and effi...

Full description

Bibliographic Details
Main Authors: Yuke TIAN, Tian TIAN, Ping YU, Li REN, Youling GONG, Wenxiu YAO, Xi ZHANG, Jun YIN, Lang HE, Li CHEN, Ke WANG, Meijuan HUANG, Juan LI
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2020-08-01
Series:Chinese Journal of Lung Cancer
Subjects:
ceritinib
anaplastic lymphoma kinase
lung neoplasms
safety
efficacy
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.33

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.33

Similar Items